Company intelligence / Profile preview

Lipomed AG

Ownership: Private
Development stage: Commercial

Overview

Lipomed is involved in the research, manufacturing, and distribution of niche pharmaceuticals for rare diseases. It has several approved drugs like Deferiprone and Cladribine.

Therapeutic areas: OncologyHematologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

cladribine

Commercial

Indications: Hairy cell leukemia, Blood cancers, Lymphoma

1 more asset in the full pipeline.

Request access →

Partnerships

Pharma Solutions (exclusive agent in several Middle Eastern countries)

Beyond the preview

Go deeper on Lipomed AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipomed AG.

Explore the full profile